Created On: 2020-07-15
Record Count: 10
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5407
The EVP will be used to research and develop such formulation(s) of EradicAide HIV Vaccine to determine feasibility for human clinical trials and eventual marketing.
The Licensee proposes that successful development of EradicAide HIV Vaccine could result in various types of formulations based upon an injectable or oral dosage form:
1) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an injectable form
2) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an oral form.
To the extent that the Licensee utilizes the Licensor's Bioral drug delivery technology, Bioral Cochleate Technology seeks to use an established, safe nutriceutical, phosphatidyl serine, to nano-encapsulate by means of our patented Cochleate structures, drugs to achieve oral delivery of therapeutic nutriceuticals that normally require injection (such as molecules with poor water solubility, large hydrophilic molecules, and protein and peptide biopharmaceuticals) and to potentially reduce toxicity and side effects frequently associated with established therapeutics.
IPSCIO Record ID: 5541
Cochleate delivery vehicles wrap-up or encapsulate the drug, rather than chemically bond with the included drug. A few of the US patents include: 1) Liposome Methods and Composition 4,663,161 2) Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles 4,871,488 Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same 3. Stabilizing And Delivery Means of Biological Molecules 5,643,574. Exhibit has excellent description of technology. The exhibit does not explain, but the original licensor is the University of Medicine and Dentistry of New Jersey who granted an exclusive worldwide license to develop the cochleate technology and in some cases co-owns the patents with the corporation.
IPSCIO Record ID: 266802
Licensor grants to a worldwide, non-exclusive license to Licensor Intellectual Property.
Patented BioralÂ® is a cochleate drug delivery technology, designed for a potentially broad base of applications.
'Component Product' shall mean any Polynucleotide Product, Drug Product or Nutraceutical
IPSCIO Record ID: 203340
Products means any product in finished pharmaceutical form for use and sale in the Field containing the Compounds formulated with and incorporating the Patents and Know-How and covered by a Valid Claim.
It is Licensee's intention to use Licensor's licensed, Bioral(TM) nanocochleate drug delivery technology to provide for oral delivery of pharmaceutical products incorporating these compounds.
IPSCIO Record ID: 5404
Under the license agreement, we and the Universities have also jointly patented certain aspects of the cochleate technology and co-own such patents with them. Our proposed drug delivery technology varies from competitors by encapsulating or wrapping the selected drug in a jellyroll-like structure termed a cochleate cylinder. All of the components of the cochleate cylinder are naturally occurring substances. We believe that the cochleate cylinder provides an effective delivery mechanism without forming a chemical bond, or otherwise chemically altering, the drug. When wrapped in our cochleate cylinders, we anticipate that these drugs may be marketed under our brand name, Bioral.
United States Patent Number 4,663,161 Issued May 5, 1987
United States Patent Number 4,871,488 Issued October 3, 1989
United States Patent Application Serial Number 08/130,986 Filed
October 4, 1993. Corres. International Application
PCT/US94/10913 Filed September 30, 1994.
United States Patent Application Serial Number 08/394,70 Filed
February 22, 1995. Corres. International Application, PCT
IPSCIO Record ID: 28542
Application serial #08/130,986 Protein or Peptide-Cochleate vaccines and methods of immunizing using the same.
IPSCIO Record ID: 27091
IPSCIO Record ID: 27964
IPSCIO Record ID: 7076
Antifungal Products shall mean any and all products covered by the patent rights licensed to Licensee by MAYO.
Technology refers to encochleated formulation of amphotericin B for topical treatments for CRS and asthma.
Appln No./Patent No.
BSZ-005: Liposome Methods and Composition US 4,663,161
BSZ-005DV: Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles
BSZ-006: Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same US 5,643,574
BSZ-006CP: Stabilizing Delivery Means of Biological MoleculesIntâ€™I (PC) US94/10913
IPSCIO Record ID: 4505